199 related articles for article (PubMed ID: 21969911)
41. Durvalumab for Extensive-Stage of Small-Cell Lung Cancer With Lambert-Eaton Myasthenic Syndrome.
Machiyama H; Minami S
J Med Cases; 2023 Feb; 14(2):71-75. PubMed ID: 36896371
[TBL] [Abstract][Full Text] [Related]
42. Pathogenic autoantibodies in the lambert-eaton myasthenic syndrome.
Lang B; Pinto A; Giovannini F; Newsom-Davis J; Vincent A
Ann N Y Acad Sci; 2003 Sep; 998():187-95. PubMed ID: 14592874
[TBL] [Abstract][Full Text] [Related]
43. Successful treatment of Lambert-Eaton myasthenic syndrome in a small cell lung cancer patient using 3,4-diaminopyridine: A case report.
Hyun JW; Kim SH; Jeong IH; Kim HT; Kim HJ
Oncol Lett; 2016 Mar; 11(3):1933-1935. PubMed ID: 26998103
[TBL] [Abstract][Full Text] [Related]
44. [Lambert-Eaton myasthenic syndrome--a rare manifestation of paraneoplastic syndrome in ovarian cancer--case report].
Zivaljević M; Popović S; Vujkov T
Med Pregl; 2005; 58(9-10):495-7. PubMed ID: 16526254
[TBL] [Abstract][Full Text] [Related]
45. Immunopathology of the Lambert-Eaton myasthenic syndrome.
Lang B; Newsom-Davis J
Springer Semin Immunopathol; 1995; 17(1):3-15. PubMed ID: 7482225
[TBL] [Abstract][Full Text] [Related]
46. Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management.
Evoli A; Liguori R; Romani A; Mantegazza R; Di Muzio A; Giometto B; Pegoraro E; Rodolico C; Vigliani MC;
Neurol Sci; 2014 Apr; 35(4):515-20. PubMed ID: 24481713
[TBL] [Abstract][Full Text] [Related]
47. SOX1 antibodies in Lambert-Eaton myasthenic syndrome and screening for small cell lung carcinoma.
Lipka AF; Verschuuren JJ; Titulaer MJ
Ann N Y Acad Sci; 2012 Dec; 1275():70-7. PubMed ID: 23278580
[TBL] [Abstract][Full Text] [Related]
48. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival.
Titulaer MJ; Klooster R; Potman M; Sabater L; Graus F; Hegeman IM; Thijssen PE; Wirtz PW; Twijnstra A; Smitt PA; van der Maarel SM; Verschuuren JJ
J Clin Oncol; 2009 Sep; 27(26):4260-7. PubMed ID: 19667272
[TBL] [Abstract][Full Text] [Related]
49. SOX-1 antibodies positive Lambert-Eaton myasthenic syndrome with occult small cell lung cancer: A case report.
Zhao L; He H; Han W; Meng Y; Kang L; Chen Y
Clin Respir J; 2024 Mar; 18(3):e13740. PubMed ID: 38497229
[TBL] [Abstract][Full Text] [Related]
50. [Dosage and specificity of anti-calcium channel antibodies in Lambert-Eaton myasthenic syndrome].
Martin-Moutot N; de Haro L; Seagar M
Rev Neurol (Paris); 2004 May; 160(5 Pt 2):S28-34. PubMed ID: 15269657
[TBL] [Abstract][Full Text] [Related]
51. Lambert-Eaton myasthenic syndrome in a patient with small-cell lung cancer: A case report.
Zhang RR; Han T; Guo F; Liu ZZ; Han YL; Chen WC; Liu YY; Xie XD
Oncol Lett; 2015 Sep; 10(3):1339-1342. PubMed ID: 26622673
[TBL] [Abstract][Full Text] [Related]
52. Clinical characteristics and long term follow-up of Lambert-Eaton myasthenia syndrome in patients with and without small cell lung cancer.
Liu Y; Xi J; Zhou L; Wu H; Yue D; Zhu W; Lin J; Lu J; Zhao C; Qiao K
J Clin Neurosci; 2019 Jul; 65():41-45. PubMed ID: 31072737
[TBL] [Abstract][Full Text] [Related]
53. Cancer detection after a 9-year course of Lambert-Eaton myasthenic syndrome complicated by anti-Hu associated limbic encephalitis.
Falso S; Spagni G; Iorio R; Evoli A
Neuromuscul Disord; 2023 Sep; 33(9):90-92. PubMed ID: 37507235
[TBL] [Abstract][Full Text] [Related]
54. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome.
Wirtz PW; Willcox N; van der Slik AR; Lang B; Maddison P; Koeleman BP; Giphart MJ; Wintzen AR; Roep BO; Verschuuren JJ
J Neuroimmunol; 2005 Feb; 159(1-2):230-7. PubMed ID: 15652424
[TBL] [Abstract][Full Text] [Related]
55. Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads.
Meriney SD; Tarr TB; Ojala KS; Wu M; Li Y; Lacomis D; Garcia-Ocaña A; Liang M; Valdomir G; Wipf P
Ann N Y Acad Sci; 2018 Jan; 1412(1):73-81. PubMed ID: 29125190
[TBL] [Abstract][Full Text] [Related]
56. Paraneoplastic cerebellar degeneration. III. Cerebellar degeneration, cancer, and the Lambert-Eaton myasthenic syndrome.
Clouston PD; Saper CB; Arbizu T; Johnston I; Lang B; Newsom-Davis J; Posner JB
Neurology; 1992 Oct; 42(10):1944-50. PubMed ID: 1407577
[TBL] [Abstract][Full Text] [Related]
57. Conjoint occurrence of GABAB receptor antibodies in Lambert-Eaton myasthenic syndrome with antibodies to the voltage gated calcium channel.
Dogan Onugoren M; Rauschka H; Bien CG
J Neuroimmunol; 2014 Aug; 273(1-2):115-6. PubMed ID: 24929678
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of durvalumab plus chemotherapy in small-cell lung cancer with Lambert-Eaton myasthenic syndrome.
Ishibashi N; Tabata T; Nonomura R; Oshima Y; Sasaki T; Mitomo H; Sugawara T; Sagawa M
Respir Med Case Rep; 2024; 47():101974. PubMed ID: 38374927
[TBL] [Abstract][Full Text] [Related]
59. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome.
Fukuda T; Motomura M; Nakao Y; Shiraishi H; Yoshimura T; Iwanaga K; Tsujihata M; Eguchi K
Ann Neurol; 2003 Jan; 53(1):21-8. PubMed ID: 12509844
[TBL] [Abstract][Full Text] [Related]
60. Small-cell lung cancer presenting with Lambert-Eaton myasthenic syndrome and respiratory failure.
Jiang JR; Shih JY; Wang HC; Wu RM; Yu CJ; Yang PC
J Formos Med Assoc; 2002 Dec; 101(12):871-4. PubMed ID: 12632823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
